Nervus vagus-stimulation til behandling af behandlingsrefraktær epilepsi

Per Jensen; Ioannis Tsiropoulos

doi:10.61409/V10230638

Nervus vagus-stimulation til behandling af behandlingsrefraktær epilepsi

Per Jensen, Ioannis Tsiropoulos

Afdeling for Hjerne- og Nervesygdomme NEU

1 Citationer (Scopus)

Abstract

About 40 % of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 % seizure frequency reduction in 50-56 % of patients. Features in the newer models offer additional treatment optimization possibilities. Side effects include hoarseness, cough, and dyspnoea. Caution is advised for patients with sleep apnoea or lung disease. VNS has specific limitations concerning MRI. This review presents an overview of VNS treatment in Denmark and discusses future challenges.

Bidragets oversatte titel	Vagus nerve stimulation for the treatment of treatment-refractory epilepsy
Originalsprog	Dansk
Artikelnummer	V10230638
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	23
ISSN	0041-5782
DOI	https://doi.org/10.61409/V10230638
Status	Udgivet - 3 jun. 2024

Emneord

Humans
Vagus Nerve Stimulation/adverse effects
Drug Resistant Epilepsy/therapy

Adgang til dokumentet

10.61409/V10230638Licens: CC BY-NC-ND

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{f409a0298cf74d07ad742f183c60c3f9,

title = "Nervus vagus-stimulation til behandling af behandlingsrefrakt{\ae}r epilepsi",

abstract = "About 40 \% of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 \% seizure frequency reduction in 50-56 \% of patients. Features in the newer models offer additional treatment optimization possibilities. Side effects include hoarseness, cough, and dyspnoea. Caution is advised for patients with sleep apnoea or lung disease. VNS has specific limitations concerning MRI. This review presents an overview of VNS treatment in Denmark and discusses future challenges.",

keywords = "Humans, Vagus Nerve Stimulation/adverse effects, Drug Resistant Epilepsy/therapy",

author = "Per Jensen and Ioannis Tsiropoulos",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = jun,

day = "3",

doi = "10.61409/V10230638",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "23",

}

TY - JOUR

T1 - Nervus vagus-stimulation til behandling af behandlingsrefraktær epilepsi

AU - Jensen, Per

AU - Tsiropoulos, Ioannis

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/6/3

Y1 - 2024/6/3

N2 - About 40 % of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 % seizure frequency reduction in 50-56 % of patients. Features in the newer models offer additional treatment optimization possibilities. Side effects include hoarseness, cough, and dyspnoea. Caution is advised for patients with sleep apnoea or lung disease. VNS has specific limitations concerning MRI. This review presents an overview of VNS treatment in Denmark and discusses future challenges.

AB - About 40 % of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 % seizure frequency reduction in 50-56 % of patients. Features in the newer models offer additional treatment optimization possibilities. Side effects include hoarseness, cough, and dyspnoea. Caution is advised for patients with sleep apnoea or lung disease. VNS has specific limitations concerning MRI. This review presents an overview of VNS treatment in Denmark and discusses future challenges.

KW - Humans

KW - Vagus Nerve Stimulation/adverse effects

KW - Drug Resistant Epilepsy/therapy

UR - https://www.scopus.com/pages/publications/85196899902

U2 - 10.61409/V10230638

DO - 10.61409/V10230638

M3 - Review

C2 - 38903031

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 23

M1 - V10230638

ER -

Nervus vagus-stimulation til behandling af behandlingsrefraktær epilepsi

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater